Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Epidemiologic features of treated end-stage renal disease in a large prepaid health plan.

Literature DB >> 2293802

Epidemiologic features of treated end-stage renal disease in a large prepaid health plan.

J D Ordonez¹, R A Hiatt, C P Quesenberry.

Abstract

We examined the incidence of treated end-stage renal disease (ESRD) among the two million members of the Kaiser Permanente Medical Care Program of Northern California from 1973 through 1985. The age-adjusted incidence rates rose from 33.9 to 81.7 per million person-years and showed no signs of stabilization. Rates were higher in men than in women and rose with age. Marked upward trends (p less than .001) in the rates of treated ESRD associated with diabetic nephropathy and hypertension were noted.

Entities: Disease Species

Mesh：

Year: 1990 PMID： 2293802 PMCID： PMC1404537 DOI： 10.2105/ajph.80.1.47

Source DB: PubMed Journal: Am J Public Health ISSN： 0090-0036 Impact factor: 9.308

11 in total

Epidemiologic features of treated end-stage renal disease in a large prepaid health plan.

1. An areawide survey of treated end-stage renal disease.

2. The frequency of kidney and urinary tract diseases in a defined population.

3. Racial factors in the incidence and causation of end-stage renal disease (ESRD).

4. Pragmatic realities in uremia therapy.

5. Characteristics of patients referred for treatment of end-stage renal disease in a defined population.

6. The incidence of treated end stage renal disease in the eastern United States: 1973-1979.

7. Does obesity explain excess prevalence of diabetes among Mexican Americans? Results of the San Antonio Heart Study.

8. The recent U.S. experience in the treatment of end-stage renal disease by dialysis and transplantation.

9. End-stage renal disease in Michigan. Incidence, underlying causes, prevalence, and modalities of treatment.

10. The Medicare experience with end-stage renal disease: trends in incidence, prevalence, and survival.

Review 1. End-stage renal disease and race: an overview and perspective.